Peptide therapy cost: what 17 U.S. offers actually charge

Peptide therapy cost in 17 U.S. offers, itemized

Across 17 published U.S. offers, selected starting subtotals ran $129 to $549, and advertised monthly, four-week or cycle prices ran $149 to $445. These offers buy different products, amounts and services; neither range establishes the full bill. The useful comparison is what each bill buys and what it still leaves unknown, not which number is smallest.

A few terms first:

• A compounded medicine is made by combining, mixing or altering ingredients for a patient’s needs. Compounded drugs are not FDA-approved finished products. (FDA explanation.)
• mg (milligram) is an amount of substance.
• mL (milliliter) is liquid volume.
• mcg (microgram) is one-thousandth of a milligram.

We list each package size so you can match like with like. These are label amounts, not directions for use.

Table 1. The peptide therapy bill matrix: 17 U.S. offers

Table 1 notes.

• Prices. All amounts are U.S. dollars, as published by each provider on the date shown. Rows are alphabetical by provider, not ranked.
• Known starting charges. These are Peptide Care Index’s sums of the named required charges or the provider’s stated package price. They are not final checkout totals or necessarily the amount paid today. The payment schedule is separate; a credited deposit is part of the price, not an extra fee.
• Blank or "not established." The provider's pages did not settle that charge. It does not mean $0.
• What a price does not show. A listed price is not FDA approval and not proof that the provider can supply that exact product to you. Several offers are limited to certain states. Rx Peps Direct says it serves 28 states plus Washington, D.C.

How we got the two ranges.

• The $129–$549 starting-subtotal range uses the 11 rows with a stated package price or a sum of named product/program, consultation/review and shipping charges: rows 2, 5, 7, 8, 10, 11, 12, 13, 14, 15 and 16. Some still have unknown required extras. A provider’s “one medication” or “one-peptide plan” label does not identify every ingredient.
• The $149–$445 period-price range uses six rows advertising a month, four-week fill or cycle: rows 1, 4, 5, 9, 10 and 11. These are unnormalized advertised units, not complete or equivalent recurring care bills. Row 6’s $225 per advertised six weeks stays separate rather than being converted into a month.
• Per-order reorders are left out of that period-price range. Rx Peps Direct ($129 for the capsule example) and Love My Peptides ($130 for its capsule example) charge per order. We do not turn their quantities or suggested-use examples into a treatment duration.

What the matrix shows

The lowest product headline is not always the lowest starting subtotal, and what “all-in” includes is a real difference between offers.

• Fees can double the product price. Rx Peps Direct's $75 capsule pack becomes $129 once the review and shipping are added. Robertson's $199 capsule bottle becomes $549 once its required consultation is added.
• Some prices include the clinician; some don’t. Pepti’s $209 is advertised as including review, ongoing care, supplies and shipping. Perfect B’s $445 includes advertised supervision and supplies; shipping was not established. Rx Peps Direct and Love My Peptides charge for the review or visit separately.
• Strength changes the price, not only the provider. Pepti lists BPC-157 at $209 for the 5 mg fill, $239 for 10 mg, $269 for 15 mg and $299 for 30 mg (Pepti, checked October 15, 2026). These are package sizes, not a recommendation to pick one. Pepti also posts $319 for a 9 mg pen, but its product selector marked the pen sold out on October 15, 2026; that posted price is not a confirmed purchasing option.
• Many offers don’t publish enough to total the bill. Six of the 17 offers lack even a settled core starting subtotal: rows 1, 3, 4, 6, 9 and 17. The other 11 have a named subtotal or package price, not proof that every required charge is included.

How much do separately listed fees add?

In four examples, separately listed fees made up 22% to 64% of the known starting subtotal. A low product price can still mean a much larger purchase. Florida’s base charge includes a program, so these percentages do not measure the full share spent on medical care.

Table 2. Product or program price versus separately listed required fees

Peptide Care Index arithmetic from the provider pages linked in Table 1. Percentages are rounded to whole numbers and use only the stated subtotals. These full purchases assume treatment proceeds; a review or consultation can still be payable without a prescription. See refunds.

What changes your answer

Your real number depends on four things the headline price usually hides:

• The exact product and amount. A 30-capsule pack, a 15 mg vial and a "four-week supply" are different purchases. A vial is a package, not a month.
• Who you pay and when. Some offers take one payment. Others split it between a review service and a pharmacy.
• Whether the price includes the clinician. If the visit is separate, add it, and check whether it repeats.
• The commitment. A plan that bills every 28 days, a three-month prepaid plan and a one-time order put very different amounts at risk.

If your quote doesn’t answer those four points, you can compare the facts it does give—but not the full bill. That’s normal. Ask for the missing lines before you commit.

The next step depends on the exact peptide, the offer, and what is still unconfirmed. Peptide Care Index's Find My Peptide Path tool lists the charges to ask about, the provider details to confirm, and questions you can copy before paying. For BPC-157, TB-500 and sermorelin, it also shows what the official records say about access. It is free, with no account or email.

Find My Peptide Path

What makes up a peptide therapy bill?

A peptide therapy quote has nine things to check: consultation, product, labs, membership, shipping, supplies, follow-up, renewals and taxes. A posted price can cover one line or a bundle. Ask for each line separately, in writing; renewal describes when charges repeat, not an extra fee to add twice.

Table 3. Nine billing checks, with amounts we found in October 2026

Examples come from the provider pages in Table 1, checked October 15, 2026. The Moonshot panel price is from its blood-panel page, checked October 15, 2026.

A missing charge is unknown, not $0. If a required charge isn't priced, the total is incomplete. Don't fill the gap with a guessed "typical lab fee." Ask for the real number.

Record these details for every quote

Use this list to turn any quote into something you can compare:

• Consultation or review: amount, who bills it, when it is charged, whether it repeats, and any written credit toward treatment.
• Product: every active ingredient; salt or form where stated (for example, free base or acetate); route, meaning how it is taken; strength; total amount; and the purchase unit.
• Required tests: which are mandatory, their prices, and whether an outside lab bills you. Keep optional tests separate.
• Membership or program fee: first charge, renewal charge, billing interval, minimum commitment, and what the fee buys.
• Shipping and supplies: what is included, what is separate, and whether it repeats.
• Follow-up: visits included versus billed separately, and how often, if the provider says.
• Tax and other mandatory charges: the actual quoted amount, not an assumed percentage.
• Amount due now: the first payment and who receives it. Tell a deposit apart from the whole price.
• Later payments and renewal: what you still owe within the commitment, the next charge date and amount.

One order, several peptides

Some services charge the review once per order, not once per peptide. That changes the math if a clinician prescribes more than one product.

Rx Peps Direct allows up to three different peptides on one order for a single $39 review and one $15 shipping charge (pricing, checked October 15, 2026). Using its listed prices:

• One order: a 15 mg BPC-157 vial ($80) plus a 15 mg sermorelin vial ($80), plus $39 and $15, comes to $214.
• Two separate orders: $134 + $134 = $268.

The $54 difference is one review and one shipping charge. This is billing arithmetic only. It is not a reason to combine peptides, and a second product is a medical decision for a clinician. Love My Peptides prices it differently: it lists $49 to add a medication to an existing plan (Love My Peptides pricing, checked October 15, 2026).

What will you pay to start, and what repeats?

Your first bill is the payment required to begin, not necessarily the whole purchase price. Your full commitment can include later payments too. Keep those two totals apart, and mark which charges come back every time.

A lower monthly price can produce a higher three-month bill

Compare the same purchase period and the same included services. A lower product price can lose its edge once required extras are added.

Hypothetical example, not provider data and not a treatment recommendation. Two made-up quotes cover the same specified product, form, amount and three-calendar-month period. Every charge is documented. The exercise does not show that the products are clinically equal or that three months of treatment is right for anyone.

Table 4. Two hypothetical quotes for the same three-month purchase

Our arithmetic from the made-up inputs above.

Quote B's monthly headline is $75 higher, but its full three-month obligation is $160 lower. Quote A also takes $195 more on day one. If you only compared $200 with $275, you'd pick the more expensive plan.

When a required charge is unpriced

Now suppose Quote A says tests are required but gives no price. The honest summary is $885 in known charges plus required tests at an unknown price. You can't say Quote A costs $885, and you can't add a guessed lab fee to make it look complete. You can say exactly what you need to ask: "What do the required tests cost, and who bills them?"

Deposits, credits and who collects each payment

A deposit that is credited toward a package is part of the price, not an extra fee. A consultation that is not credited stays a separate charge.

• Hypothetical: a $100 deposit credited against a $400 package means $400 total: $100 today and $300 later, not $500.
• Real example (Rx Peps Direct, 15 mg BPC-157 vial):
  • You pay $39 to Rx Peps Direct at checkout for the medical review.
  • After approval, the pharmacy bills $80 for the vial and $15 for shipping.
  • The order totals $134, paid to two different businesses.
  • Source: Rx Peps Direct pricing, checked October 15, 2026.

That split matters if something goes wrong, because each business has its own refund rules (see refunds).

Perfect B supplies another real deposit example: its treatment-plan page advertises a $150 consultation deposit credited toward treatment. Against the listed $445 plan, that would leave $295 of the plan price after the credit, not turn the plan into $595. Confirm that the quoted plan qualifies, when the balance is due and what happens to the deposit if treatment does not proceed. (Deposit terms; our arithmetic.)

How much does peptide therapy cost per month?

The selected monthly, four-week and cycle prices in Table 1 run $149 to $445 before any unpriced required extras. Its six-week tesamorelin offer is $225; per-order prices remain separate. A calendar month, 28-day fill, order and clinic-defined cycle are different units, so keep the seller’s real unit next to every price.

Table 5. What "monthly" can mean

Count the real billing periods

A 28-day fill is not a calendar month. Over a long stretch the difference adds up. Billing arithmetic only, not a prediction of how long anyone should continue:

• Pepti BPC-157, unchanged $209 advertised four-week fill: 13 fills = $2,717 for thirteen four-week supply periods, or 364 days. Twelve fills would be $2,508 and represent 336 days. This assumes the price and four-week interval stay unchanged; Pepti’s terms also allow an adjusted prescribed-supply interval. Count actual payment dates separately. (Price; billing terms, checked October 15, 2026.)
• Standard-price Wegovy injection, $349 per 28-day fill through NovoCare: 13 fills = $4,537 for 364 days of labeled supply, before any visits (NovoCare terms, checked October 15, 2026). Twelve fills = $4,188 and cover 336 days.

A hypothetical 28-day billing schedule starting October 1 would next charge on October 29. At $209 each, those two charges total $418 in October. Conversely, a window that includes both day 0 and day 364 contains 14 charge dates at an exact 28-day interval—not 13. The bill depends on which dates your budget includes, not a blanket “13 charges every year.”

Per-order services: count what repeats

When a service charges per order, the fees come back each time.

• Rx Peps Direct: two capsule orders cost $129 + $129 = $258, not $129 + $75. The $39 review and $15 shipping repeat (pricing).
• Love My Peptides: the $99 initial visit covers a 30-day check-in, so a reorder of the same capsule pack is $115 + $15 = $130 until the $99 annual follow-up comes due (pricing).

Why we don't turn a vial into a month

A vial's label tells you the amount inside, not how long it lasts. That depends on the prescribed amount, which is a clinical decision. Pepti and Love My Peptides say the same: how long a vial lasts depends on the dose your prescriber sets. So we price vials as vials and never divide them into "monthly" costs for you. For BPC-157 specifically, our BPC-157 monthly cost guide shows how capsule, vial and program prices compare.

Do prepaid plans, stacks and financing save money?

A longer plan can lower the average per month while raising the full commitment. In one published example, six cycles cost $825 less than six single cycles, but mean committing $1,845 instead of $445. That price comparison assumes all six purchases; it does not establish payment timing or a saving from stopping early.

Table 6. Perfect B’s one-peptide plan: single-cycle purchases vs. longer plans

Prices from Perfect B, Doral, Florida, checked October 15, 2026. The clinic defines a cycle as one month. Whether a multi-cycle plan is charged all at once, and what is refunded if you stop early, were not established.

What the averages mean. The $307.50 "per month" figure is an average over a $1,845 plan. It is not a price you can pay for one month. If the six-cycle plan is charged at the start, the first payment is $1,845, and stopping after two cycles does not reduce that $1,845 commitment unless unused cycles are refunded. Ask for that in writing.

Table 7. Perfect B's stack tiers, per cycle

Source as Table 6. A higher tier is a bigger purchase. It is not evidence that combining peptides works better, and the clinic prices all its peptides alike within a tier.

Two more multi-month examples

• AgelessRx sermorelin:
  • The $99 "first month" applies only to a three-month plan billed in full, with $149 a month after.
  • The page does not state the single amount charged up front.
  • We don't add it up for you: $99 + $149 + $149 = $397 would be a guess about how the plan is billed, and the checkout total is what counts.
  • Offer, checked October 15, 2026.
• Moonshot Medical BPC-157:
  • $635 for an advertised three months works out to $635 ÷ 3 = $211.67 a month, against $250 for one month.
  • Whether the $635 is prepaid, and what the in-person startup visit costs, were not established.
  • Plans, checked October 15, 2026.

Introductory prices and financing answer different questions

An introductory price tells you what qualifying early purchases cost, not the lasting price. A financing payment tells you a repayment amount, not what treatment costs each month.

• Introductory example:
  • NovoCare lists $199 for each of the first two qualifying 28-day fills of Wegovy injection at the 0.25 mg or 0.5 mg strength, for patients new to that program.
  • The prescription must be written and received by December 31, 2026, and shipped by January 31, 2027.
  • After that, the standard $349 price applies at standard strengths.
  • Strengths are listed here only to identify the offer. They are a prescriber's decision, not a way to save money.
  • NovoCare terms, checked October 15, 2026.
• Financing example (hypothetical): a $600 purchase repaid in twelve $50 installments is still a $600 obligation before interest or fees. It does not buy twelve months of supply. Perfect B’s cost guide labels its “from $18/month” example as financing, not a monthly product price. Ask for the total repaid and what happens to the loan if care stops.

What if you aren't prescribed, cancel, or the pharmacy can't fill it?

No prescription does not always mean no charge. A medical review, a pharmacy order and a shipped product can each have their own refund rule. Ask what each payment buys and when it stops being refundable.

Table 8. Money at risk: published refund and cancellation rules

Provider-published terms, not a guarantee of any refund decision and not legal advice about a dispute. "Not established" means we didn't find the rule, not that there are no refunds.

The difference between "not charged" and "charged, then refunded" matters for your cash. A refund can take days to post. If a provider's pages describe both, plan for the money to leave your account until they confirm otherwise in writing.

Cancelling future charges is not the same as refunding this order

Stopping a renewal may not cancel work already underway. Ask separately whether cancelling stops the next charge, the order the pharmacy is already preparing, or both. Pepti’s billing terms allow cancellation of future renewals but distinguish an order already in progress. Rx Peps Direct’s current pricing page offers optional automatic refills that can be turned off in the dashboard, despite broader “no subscription” wording in its cost article. No membership does not necessarily mean no recurring orders.

If you've already paid and something went wrong:

• Use the official contact route of the business that collected that payment. For a pharmacy charge, that may be the pharmacy, not the clinic.
• Keep the receipt, the charge date and the cancellation confirmation together.
• Don't send medical or payment records to Peptide Care Index.

For BPC-157 offers, our BPC-157 refund comparison covers more providers.

FDA-approved peptide medicines are priced differently

Some peptides are FDA-approved medicines with manufacturer cash prices and possible insurance coverage. Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound) are examples. Their prices are not like-for-like comparisons with the BPC-157 or compounded sermorelin offers above, which are different products proposed for different reasons. Approval belongs to a specified finished product and its labeling, not every preparation containing a similarly named ingredient. (FDA-hosted Wegovy labeling, Ozempic labeling, Zepbound labeling; Wegovy HD approval.)

Table 9. Manufacturer self-pay prices for three FDA-approved peptide medicines

Sources: NovoCare pharmacy terms, Wegovy pricing, Ozempic savings, LillyDirect Zepbound and Lilly terms, checked October 15, 2026. Strengths identify the offer; they are not a dose choice. These are drug-only prices, not an included-care package; confirm visit and test charges separately. NovoCare requires a valid prescription for an FDA-approved indication under the product’s labeling. Its introductory “new patient” definition means no prior injection fill for that brand through NovoCare or NovoCare Legacy; prescriptions must be both written and received by the stated deadline. These self-pay prices are not insured copays, and the programs’ reimbursement restrictions still apply.

Two things make these different from the compounded offers in Table 1. First, the drug itself has gone through FDA review for specific uses. Second, a plan or government program can have a defined benefit for an exact approved product; the advertised compounded prices in Table 1 do not establish such a benefit. Our FDA-approved peptides list shows which peptide products have approval, and the peptide price list has every manufacturer row.

Will insurance, Medicare, HSA or FSA lower the bill?

For the advertised compounded offers here, budget from the cash quote unless your plan confirms otherwise. We did not establish an insured product price for any Table 1 offer. Coverage depends on the exact drug, its use and the plan or program; the visit, the labs and the drug each get their own answer.

Compounded peptides: assume cash

Pepti says its compounded BPC-157 is not covered by insurance or Medicare (cost page, checked October 15, 2026). Perfect B says the same about compounded peptides generally (cost guide, checked October 15, 2026). Those are provider statements, not an insurer's rule, and we haven't checked every plan. But we found no compounded offer advertising an insured price.

A clinic that "accepts insurance" for office visits isn't telling you the peptide is covered. Ask your plan about each item by name: "For this exact prescription, is there coverage? Is the consultation billed to insurance? Are the required tests?"

Medicare Part D: compounded ingredients and the GLP-1 Bridge

Medicare's drug-plan manual says bulk powders, the raw ingredients pharmacies compound from, are not Part D drugs (CMS Part D Benefits Manual, chapter 6, section 10.4, checked October 15, 2026). Coverage of a compounded prescription is limited to its qualifying Part D parts. A compounded BPC-157 ingredient doesn't become covered because a pharmacy mixed it. The current compounded-product regulation also distinguishes qualifying Part D ingredients from the rest of a compound.

Separately, there is a specific program for certain weight-management GLP-1 medicines—not an exception that makes bulk compounded ingredients covered. CMS's Medicare GLP-1 Bridge runs from July 1, 2026, through December 31, 2027, and gives eligible people with Part D a $50 copay (CMS overview; CMS provider information, both checked October 15, 2026). The fine print matters:

• Eligible products only: Foundayo, Wegovy (injection and tablets) and the Zepbound KwikPen. Zepbound single-dose vials and single-dose pens are not included. Foundayo is a non-peptide GLP-1 medicine; it is named here to describe the Bridge’s full product list, not to reclassify it as a peptide. (Molecule description.)
• Weight management only: the prescriber must submit prior authorization showing the person meets CMS’s age, body-mass-index and condition criteria. CMS directs people with type 2 diabetes, obstructive sleep apnea or MASH (a liver condition) to the appropriate Part D coverage route rather than the Bridge; the relevant drug and indication still need to qualify.
• Outside the normal Part D benefit: the Part D deductible doesn't apply, the $50 doesn't count toward your yearly out-of-pocket total, and Extra Help (the low-income subsidy) doesn't apply.
• Pen needles aren't covered, and there is no appeals process, though a prescriber can resubmit.

This is not Medicare coverage for peptide therapy in general. If you have Part D and are considering one of these medicines, ask your prescriber or pharmacist about the Bridge, or check Medicare.gov. We can't tell you whether you qualify.

HSA or FSA: card acceptance isn't approval

A health savings account (HSA) or flexible spending account (FSA) can pay for qualified medical expenses. But a card going through doesn't prove the expense qualifies. Pepti says HSA and FSA cards are "usually accepted," and AgelessRx advertises HSA/FSA. Those are payment-acceptance statements, not tax rulings.

The IRS explains the rules in Publication 969 for HSAs and other health accounts, and Publication 502 for medical expenses; the editions reviewed are for 2025. A general wellness purchase does not automatically qualify. Also check the purchase program’s own restrictions rather than assuming a health-account payment or reimbursement is allowed. Keep itemized receipts. Ask your FSA administrator about the exact expense, and a tax professional if you're unsure about an HSA. We don't subtract presumed tax savings from any price on this page.

Why are research-use peptides so much cheaper?

A research-only vial is sold as a laboratory product, not a clinical service with an evaluation, prescription and follow-up. Its stated research purpose does not make it suitable for human treatment. It isn’t a cheaper version of therapy; it is a different category of purchase.

For example, one seller lists a 5 mg BPC-157 research item at $60, and its terms limit the product to laboratory research, not human or veterinary use (listing; terms, checked October 15, 2026). The listing also marks a $30 add-on as required, so $60 is not an established checkout total; shipping, tax and purchasing requirements remain separate. We include it only to explain the category difference, not as a supplier or an option for treatment.

Some things a price can't tell you:

• A certificate of analysis reports specific tests on a stated sample. It doesn't prove sterility unless a sterility test is reported. It also doesn't show that the product is safe, effective or legal to supply to you.
• No price threshold proves a product is genuine. A low price doesn't prove a fake, and a high price doesn't prove quality.
• "Pharmaceutical grade" wording on a website is a claim, not a test result.

Our peptide purity testing statistics and peptide recalls pages show what product testing and recalls have found.

Does a posted price mean the clinic can supply the peptide?

No. A price shows what a clinic advertises, not that it can lawfully supply that exact product to you. FDA’s staff briefings identify no approved drug component for the BPC-157 or TB-500 free-base/acetate forms they evaluated; neither name appears in the checked 503A bulks list. Those findings do not settle every ingredient pathway or a patient-specific fill.

Section 503A sets conditions for certain drugs compounded by licensed pharmacists or physicians, generally for identified patients. Its bulk-ingredient conditions include an applicable USP/NF monograph, a component of an FDA-approved drug, or inclusion on the finalized 503A bulks list; FDA also describes an interim enforcement policy. The codified list is therefore not the only ingredient criterion. Here is what the official records show. (FDA’s 503A framework.)

• No approved BPC-157 drug. FDA staff wrote that neither BPC-157 free base nor BPC-157 acetate is a component of an FDA-approved drug, and that no official quality standard (a USP or NF monograph) exists for either (FDA briefing, page 9, staff evaluation dated May 11, 2026; checked October 15, 2026).
• Not on the finalized 503A bulks list. BPC-157 and TB-500 do not appear in 21 CFR 216.23, in the version displayed as current through October 13, 2026, when checked on October 15. This is a finding about that list, not a complete ruling on every possible transaction.
• TB-500 is not full-length thymosin beta-4. The FDA TB-500 briefing, printed pages 7 and 25, evaluates the free base and acetate of a seven-amino-acid fragment, not the full 43-amino-acid molecule. It identifies neither evaluated form as a component of an FDA-approved drug. A clinic’s “TB-500” name alone does not prove which substance it intends to supply.
• Withdrawn nominations with safety concerns. FDA's safety page lists BPC-157 and the TB-500 fragment among substances whose nominations were withdrawn after earlier placement in its "category 2." It describes possible immune reactions for some routes, impurity questions, and little or no human safety information (FDA, checked October 15, 2026).
• An advisory vote is not approval. FDA's compounding advisory committee met July 23–24, 2026. It discussed BPC-157 (the use FDA reviewed was ulcerative colitis), TB-500 (wound healing), KPV, MOTS-c, emideltide, Semax and epitalon. FDA says advisory committees make non-binding recommendations (FDA meeting page, checked October 15, 2026). News reports describe the panel as recommending six of the seven (AJMC, August 21, 2026). We did not find a vote summary or minutes on the FDA meeting page when checked. The six-of-seven tally remains attributed reporting, not a vote record we independently inspected. The checked codified list still does not include BPC-157 or TB-500; no final action adding them was located in this audit’s targeted FDA/Federal Register search. A favorable advisory recommendation would not itself approve a drug or establish a particular provider’s access route.
• Compounded isn't approved. FDA says compounded drugs are not FDA-approved, and that it doesn't check their safety, effectiveness or quality before they're sold (FDA Q&A).

“Off-label” has a different meaning: using an FDA-approved medicine outside its approved labeling. It does not turn an unapproved compounded product into an approved drug. (FDA’s explanation.)

Why this matters for your budget. If the rules change, which pharmacies can supply a peptide and what they charge may change too. We don't predict either. A provider saying it uses a "licensed pharmacy" doesn't settle the ingredient question on its own. We haven't reviewed the compounding basis for sermorelin, tesamorelin or the other peptides in Table 1, so we don't state one.

The Peptide Care Access Check, applied to price claims

The Peptide Care Access Check attaches a finding to one specific requirement, never to a whole provider. Its labels are:

• Supported: the evidence shows the requirement is met.
• Contradicted: the evidence shows it isn't.
• Unresolved: we can't settle it with what we have.
• Conflicting: sources disagree.
• Not applicable: the item doesn't answer the question being asked.

None of these is a safety or quality rating.

Table 10. Access Check findings for price claims on this page

A price can be clear while the supply question stays open. For BPC-157, TB-500 and sermorelin, Peptide Care Index's Find My Peptide Path tool lays out what the dated official records establish, what they don't, and the next check to make. For any other peptide, it gives you the provider and fee checklist to send before paying.

Find My Peptide Path

For more depth, see BPC-157 FDA approval and compounding status, the FDA peptide compounding list and status table, FDA peptide hearing dates and records, how to get BPC-157 in the U.S., and FDA warning letters about peptides.

Why do other cost guides say $150 to $2,000 a month?

The four guides below report very different scopes: broad market estimates, reported spending, or one clinic’s own prices. Their headline endpoints span more than tenfold, but they are not estimates of the same purchase. A range is only useful if you can see what’s behind it.

Table 11. Published peptide therapy cost ranges and what each says it's based on

Pages read October 15, 2026. This table describes what each page says about its own basis. It is not a judgment of the clinics' care.

The ranges above aren’t necessarily wrong. The three broad estimates do not provide the itemized underlying offers needed to reproduce them; Perfect B does publish its own plan prices. Our narrower ranges describe only the selected, linked offers and stated units in Table 1—not the whole market or a proven lower-cost treatment. Table 1 shows which rows feed each number. When a row changes, the range changes with it.

Is peptide therapy worth the cost?

The prices on this page tell you what is advertised, not what clinical result you would get. These offers and the examples below do not establish a reliable “cost per result.” Whether to spend is a medical question for you and a clinician. Whether a quote is complete is one you can answer today.

Here is what the evidence looks like, in the precise terms that matter for spending:

• BPC-157.
  • An often-cited 2021 knee-pain report (Lee and Padgett) looked back at one clinic’s patients: 11 of 12 respondents who received BPC-157 alone reported less knee pain. The report reviewed 17 charts, reached 16 people and analyzed the four combination-treatment respondents separately.
  • It had no comparison group and relied on self-report.
  • It used injection into the knee joint, not the capsules or under-the-skin injections priced above.
  • That justifies further study. It doesn't tell a buyer what their purchase will do.
  • Full register: BPC-157 human studies.
• TB-500. Evidence about full-length thymosin beta-4 doesn’t automatically apply to the seven-amino-acid TB-500 fragment evaluated by FDA. Confirm the exact identity behind a clinic’s product name. See TB-500 human studies.
• Provider satisfaction numbers aren't trials.
  • AgelessRx's sermorelin page says 90% of customers saw noticeable results by their second check-in.
  • Its footnote says that figure is self-reported by 392 surveyed customers approved for sermorelin who were between their second and third check-in from August 5, 2025, through January 22, 2026 (AgelessRx, checked October 15, 2026).
  • With no comparison group, it can't separate the treatment's effect from expectation or from who chose to keep going.

To compare substances by evidence and safety, use the peptide comparison chart and peptide side effects chart.

Our verdict. These sources support comparing bills and spotting incomplete quotes. They don't identify a "best value" provider, and they don't show that paying more buys a better result. What a higher price can usefully buy is documented service:

• a named dispensing pharmacy;
• included follow-up;
• clear refund terms;
• a clinician who will tell you what outcome would mean it's time to stop paying.

If a premium doesn't come with those things in writing, it's just a higher price.

Ways to lower financial risk without changing treatment:

• Ask for an itemized quote.
• Clarify whether a consultation is credited.
• Separate optional extras from required ones.
• Check real coverage for an FDA-approved medicine.
• Compare the full commitment before prepaying.
• Turn off renewals you don't want.

Don't save money by stretching a vial, changing the amount you take, or buying research-use products. Those change the treatment, not the price.

Check a quote before you pay

Turn any quote into three numbers: what's due today, what each later bill will be, and the total for the number of periods your quote covers. Keep every unpriced charge visible. Then send the questions below to fill the gaps.

Table 12. Quote worksheet (works on paper or screen)

For a paper comparison, write every required charge once, then mark when it is paid: today, a specified later bill, or later at a date still unknown. Add all charges for the quoted commitment to get the cost; add only payments due today to get today’s bill. A $75 follow-up due later belongs in the full cost but not today’s payment.

When a plan price includes several periods, do not add the included product charges again. A $100 deposit credited toward a $400 package divides the payment into $100 and $300; it does not change the $400 price. A genuine discount or a separately charged consultation credit changes the cost only as the written terms specify.

Mark a missing amount unknown, an expressly waived charge $0, and an item inside the bundle included. Unknown payment timing can leave today’s bill unresolved even when the full price is known. Compare totals only when both quotes cover the same documented purchase period and scope—not merely the same number of differently sized “periods.”

Copy this quote request

Before I pay, please identify the exact service and product being considered: every active ingredient, the form or salt where applicable, how it is taken, the strength, the total amount, and the period this purchase covers. Please name the dispensing pharmacy and tell me what supports supplying this exact product in my state.

Please itemize the consultation or review, product, required tests, membership, shipping, supplies, required follow-up, and any taxes or other charges. Mark each item as included, separately required, optional, or not applicable, and tell me who collects each payment.

What is due now, what must be paid later within the same commitment, and what will the next purchase cost? Is any deposit credited toward the package? Is the billing unit a calendar month, 28 days, one order, or a longer plan? Please give the full commitment, not only a monthly equivalent.

Does anything renew automatically, and what is the next charge date? How do I stop future charges, and what happens to an order already being processed?

If no prescription is written, what is kept? If a prescription is written but can't be filled, who refunds the product and shipping? What happens to unused services or supplies in a prepaid plan?

Please send the clinic and pharmacy terms in writing before collecting any nonrefundable payment.

How we checked these prices

We read the linked provider price and service pages and the fee, billing or refund terms available for the claims reported here, added only the charges they name, and kept every unpriced charge as unknown. Official FDA, CMS and IRS records support only the narrower regulatory and payment facts stated beside them. Reading a source is not a completed purchase or a confirmation that a product can be supplied.

Peptide Care Index is the independent decision and access index for peptide care—helping you understand the route, the cost, the evidence, and the next step before you pay.

What we actually checked

Sources:

• 17 published U.S. offers from 13 providers, plus their fee, billing and refund pages;
• manufacturer self-pay terms from NovoCare and LillyDirect;
• FDA’s July 2026 advisory meeting page, the relevant sections of its BPC-157 and TB-500 staff briefings, its compounding Q&A/framework and its safety page for bulk substances;
• the codified 503A bulk list (21 CFR 216.23);
• CMS's Part D manual and Medicare GLP-1 Bridge pages;
• IRS Publications 969 and 502;
• four published cost guides;
• one original BPC-157 report, including its methods, respondent counts and results;
• FDA-hosted product labeling and the Wegovy HD approval announcement for the approved medicines identified here.

The advisory vote tally is attributed to the named news report, not an FDA vote record we inspected. That report does not establish final approval or a supply route.

Dates:

• The sources supporting the retained offer, manufacturer, coverage and research claims were read or re-read October 15, 2026.
• Source publication dates remain separate: for example, FDA’s BPC-157 staff evaluation is dated May 11, 2026; Rx’s cost article dates its prices to September 17; Pepti’s formal policies are dated August 8.
• The eCFR page displayed currency through October 13, 2026. A source check on October 15 does not extend that displayed version.
• Each table shows its source-check date; this is not a claim that the offer was newly announced that day.

How offers were chosen:

• We picked published offers with patient-facing prices or terms we could link, chosen to show different payment structures.
• This is not a survey of the whole U.S. market and not a ranking.
• Rows are alphabetical.

What we did not do:

• We completed no checkouts and bought or tested no products.
• We didn't contact providers, check licenses, inspect pharmacies, or confirm state availability for anyone.
• Prices and service descriptions remain provider-published.
• No clinician, pharmacist or regulatory specialist reviewed this page.
• AI assisted the research and drafting; editorial source review is not specialist review.

Our research methodology explains the Access Check and how we compare offers. Our editorial standards cover corrections and AI assistance. The provider links on this page are unpaid; see how we make money. If a price here has changed, tell us through contact and corrections with the public source. Please don't send medical records or payment details. A changed price should change its row, the ranges and every example that uses it, not just the date.

Other questions about peptide therapy cost

How much does peptide therapy cost per session?

None of the 17 offers we checked priced therapy per session; they bill per order, per fill, per month or per cycle. If a clinic quotes a per-session price, ask what one session includes (a visit, an in-clinic injection, take-home product) and how many sessions the quote assumes. Then compare the total, not the session price, with a monthly offer.

What is the cheapest peptide therapy?

The lowest documented starting subtotal in our selected priced offers was $129: Rx Peps Direct’s 30-capsule BPC-157 pack with its $39 review and $15 shipping. That is a subtotal comparison, not proof of the cheapest complete or clinically equivalent treatment; several offers and required extras remain unpriced. It also doesn’t settle whether that product can be supplied to you or is right for you. Rx Peps Direct says it serves 28 states plus Washington, D.C.

Why don't more clinics post their prices?

The reviewed pages do not establish why each clinic leaves a price unpublished. A prescription-specific product or amount can change a quote, but missing prices alone do not establish a problem with care. Ask for an itemized written quote before you pay anything nonrefundable. Six of our 17 offers lacked even a settled core starting subtotal; others still left required extras unresolved.

Does peptide therapy cost more in some states?

These offers do not establish a state-by-state price difference. Availability is a separate question. Several offers here are limited to one state (Florida, California, or in-person in Illinois). Others advertise a service area: 28 states plus D.C. for Rx Peps Direct, and 50 states on Pepti’s cost page. Those are provider claims, not our license or patient-specific dispensing checks. We don't publish state averages because the offers don't support one.

You now know what a complete peptide therapy quote looks like. To check what the official records say about access, and to prepare the provider and fee questions that are still open, use Find My Peptide Path. It's free, with no account or email, and it doesn't ask for your medical history.

Find My Peptide Path

Sources and check dates

Each price and claim above links to its exact source beside it. This list groups them so you can inspect the research. Provider pages establish what each business advertises, not confirmed fulfillment or treatment results. Official records support only the narrower statements made beside them.

Provider prices, fees and refund terms

• AgelessRx: Sermorelin injection offer (checked Oct 15, 2026); FAQ (Oct 15, 2026)
• Bridgeside Telehealth: Peptide telehealth program (Oct 15, 2026)
• Defy Medical: Get started (Oct 15, 2026)
• EDGE Integrative Wellness: Peptide menu (Oct 15, 2026)
• Florida Surgery & Weight Loss Center: BPC-157 program (Oct 15, 2026)
• InfusaLounge: Pricing (Oct 15, 2026)
• Love My Peptides: Pricing, visits and shipping (Oct 15, 2026)
• Moonshot Medical: Peptide plans, in-person BPC-157 evaluation, consultation condition and blood panels (Oct 15, 2026)
• Pepti: BPC-157 cost, product selector, refund policy, billing policy and terms for combined orders (Oct 15, 2026)
• Perfect B: Peptide therapy cost guide and treatment plan, deposit and optional panel (Oct 15, 2026)
• Robertson Wellness & Aesthetics: BPC-157 products; peptide consultation (Oct 15, 2026)
• Rx Peps Direct: Pricing and payment example (Oct 15, 2026); BPC-157 cost, sermorelin, refund policy (Oct 15, 2026)
• Valhalla Vitality: Homepage (Oct 15, 2026)

Manufacturer programs

• NovoCare pharmacy terms; Wegovy pricing; Ozempic savings (Oct 15, 2026)
• LillyDirect Zepbound; Lilly self-pay terms (Oct 15, 2026)

Regulatory records

• FDA-hosted Wegovy labeling (February 2026), Ozempic labeling (May 2026), Zepbound labeling (January 2026), and Wegovy HD approval announcement (March 19, 2026). Used for the specified approved product identities, not as personal dosing guidance; checked Oct 15, 2026.
• FDA: BPC-157 staff briefing, especially printed page 9, dated May 11, 2026; TB-500 staff briefing, especially printed pages 7 and 25; 503A bulk-substance framework; off-label explanation (checked Oct 15, 2026)
• FDA: Bulk drug substances that may present significant safety risks (Oct 15, 2026)
• FDA: July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting (Oct 15, 2026)
• FDA: Compounding and the FDA: Questions and Answers (Oct 15, 2026)
• eCFR: 21 CFR 216.23 (checked Oct 15, 2026; displayed current through Oct 13, 2026)
• Attributed news report on the advisory vote: AJMC, August 21, 2026 (read Oct 15, 2026; not an inspected FDA vote record or a final agency action)

Coverage and tax

• CMS: Medicare GLP-1 Bridge and information for providers (Oct 15, 2026)
• CMS: Part D Benefits Manual, chapter 6, section 10.4, PDF pages 5–6 (manual revision January 15, 2016); 42 CFR 423.120(d) (displayed current through October 13, 2026). Both checked Oct 15, 2026.
• IRS: Publication 969 and Publication 502, 2025 editions (checked Oct 15, 2026)

Research and other

• Lee and Padgett, 2021, intra-articular BPC-157 knee report (Oct 15, 2026)
• Research-use example: American Peptides listing and terms (Oct 15, 2026)
• Published cost guides: Pur Life Med Spa, Ubie Doctor's Note, InCare (Oct 15, 2026)

Related on Peptide Care Index:

• Peptide price list: 40 U.S. offers, sizes and fees
• BPC-157 cost
• Compare online peptide therapy providers